Sensei Biotherapeutics Reports Results from Phase 1 Clinical Trial of SNS-301, a First-in-Class Cancer Immunotherapy Targeting ASPH, a Novel Tumor-Specific Antigen

SNS-301 demonstrated a favorable safety profile, improvements in disease parameters, and robust antigen-specific immune responses Clinical results presented in Poster Discussion session at ESMO 2018 Company to initiate Phase 2 study of SNS-301 in multiple solid tumor indications and hematological malignancies in early 2019 GAITHERSBURG, Md.–(BUSINESS WIRE)–Sensei Biotherapeutics, Inc., a clinical-stage biopharmaceutical company developing precision…

Details

Sensei Biotherapeutics to Present Clinical Data at Upcoming Oncology Medical Conferences

Data to highlight SNS-301, a first-in-class cancer immunotherapy targeting ASPH, a novel tumor-specific antigen GAITHERSBURG, Md.–(BUSINESS WIRE)–Sensei Biotherapeutics, Inc., a clinical-stage biopharmaceutical company discovering and developing precision immuno-oncology therapies, today announced that it will present clinical data for SNS-301, its first-in-class cancer immunotherapy candidate, at two upcoming oncology medical meetings. READ MORE

Details

Sensei Biotherapeutics Appoints Ildiko Csiki, M.D., Ph.D., as Chief Medical Officer

GAITHERSBURG, Md.–(BUSINESS WIRE)–Sensei Biotherapeutics, Inc., a privately-held biopharmaceutical company developing immuno-oncology therapies that teach the immune system to recognize and attack cancer, today announced the appointment of Ildiko Csiki, M.D., Ph.D., as Chief Medical Officer. Dr. Csiki brings nearly two decades of leadership experience in oncology drug development and research, most recently serving as Vice…

Details

Sensei Biotherapeutics Reports New Data from Phase 1 Clinical Trial of SNS-301

SNS-301 demonstrated a strong safety profile and promising immune responses in patients with biochemically recurrent prostate cancer SNS-301 is a first-in-class immunotherapy candidate emerging from Sensei’s SPIRIT platform that targets a novel embryonic antigen found on more than 20 types of cancers GAITHERSBURG, Md.–(BUSINESS WIRE)–Sensei Biotherapeutics, Inc., a privately-held biopharmaceutical company developing immuno-oncology therapies that…

Details

Sensei Biotherapeutics Appoints John Celebi as President and Chief Executive Officer

Experienced Biotechnology Executive to Lead Company’s Growth Strategy for Cancer Immunotherapies, Including Lead Clinical Candidate SNS-301 GAITHERSBURG, Md.–(BUSINESS WIRE)–Sensei Biotherapeutics, Inc., a privately-held biopharmaceutical company developing immuno-oncology therapies that teach the immune system to recognize and attack cancer, today announced the appointment of John Celebi, M.B.A., as President and Chief Executive Officer. He also joins…

Details